A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia

Blood

Volumn 90, Issue 12, 1997, Pages 4710-4718

  Heil, Gerhard ^a   Hoelzer, Dieter ^b   Sanz, Miguel A ^b   Lechner, Klaus ^b   Liu Yin, John A ^b   Papa, Giuseppe ^b   Noens, Luc ^b   Szer, Jeff ^b   Ganser, Arnold ^b   O'Brien, Caroline ^b   Matcham, James ^b   Barge, Alan ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 6844251615     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.12.4710.4710_4710_4718     Document Type: Article

References (43)

1. Sebban C, Archimbaud E, Coiffier B, Guyotat D, Treille-Ritouet D, Maupas J, Fiere D: Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer 61:227, 1988
2. Rees JK, Gray RG, Swirsky D, Hayhoe FG: Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet ii:1236, 1986
3. Rees JK, Gray D: Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia. MRC ninth AML trial. Semin Oncol 14:32, 1987 (suppl 1)
4. Stone RM, Mayer RJ: The approach to the elderly patient with acute myeloid leukemia. Haematol Oncol Clin North Am 7:65, 1993
5. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S, Stryckmans P: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268, 1989
6. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164, 1991
7. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29:319, 1993
8. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430, 1992
9. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Weite K, Souza L: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414, 1988
10. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM: Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891, 1989
11. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T: Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 15:261, 1995
12. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281, 1993
13. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675, 1996
14. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 11:328, 1997
15. Büchner T, Hiddemann W, Wörmann B, Zühlsdorf M, Rottmann R, Innig G, Maschmeyer G, Ludwig W, Sauerland MC, Heinecke A: Hematopoietic growth factors in acute myeloid leukemia: Supportive and priming effects. Semin Oncol 24:124, 1997
16. Terpstra W, Löwenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11:315, 1997
17. Büchner T, Hiddemann W, Wörmann B, Rottmann R, Zühlsdorf M, Maschmeyer G, Ludwig WD, Sauerland MC, Frisch J, Schulz G: GM-CSF multiple course priming and long-term administration in newly diagnosed AML. Hematopoietic and therapeutic effects. Blood 84:27a, 1994 (suppl 1. abstr)
18. Rowe JM, Andersen J, Mazza JJ, Bennett JM, Paietta E, Hayes A, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A Randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (ECOG). Blood 86:457, 1995
19. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332:1671, 1995
20. Löwenberg B, Suciu S, Zittoun R, Ossenkoppele GJ, Boogaerts M, Wijermans PW, Vellenga E, Berneman ZN, Dekker AW, Sonneveld P, Stryckmans P, Solbu G, Dardenne M, de Witte T, Archimbaud E: GM-CSF during, as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC-HOVON Phase III Trial (AML 11). Blood 86:433a, 1995 (suppl 1, abstr)
21. Witz F, Harousseau JL, Sadoun A, Guyotat D, Berthou C, Cahn JY, Gardin C, Lioure B, Witz B, Desablens B, Ifrah N, Pignon B, Leprise PY, Audhuy B, Caillot D, Casassus P, Linassier P, Christian B, Hurteloup P, Polin V, Tellier Z: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Blood 86:512a, 1995 (suppl 1, abstr)
22. Löwenberg B, Boogaerts MA, Vellenga E, Ossenkoppele GJ, Dekker AW, van der Lelie J, Schouten HC, Fopp M, Gratwohl A, Fey M, Gmur J, van Putten WJL: Various modalities of use of GM-CSF in the treatment of acute myelogenous leukemia (AML). A Hovon-sakk randomized study (HOVON-4A). Blood 86:512a, 1995 (suppl 1, abstr)
23. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, Nicolay U, Gaus W, Heimpel H: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de-novo acute myeloid leukemia (AML). Leukemia 5:3, 1995
24. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150, 1996
25. Godwin JE, Kopecky K, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR: A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 86:434a, 1995 (suppl 1, abstr)
26. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678, 1995
27. Ohno R, Tomonaga M, Kobayashi T, Kanamuru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871, 1990
28. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N, and the Kohseisho Leukemia Study Group: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments]. Blood 83:2086, 1994
29. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626, 1985
30. Whitehead J, Stratton I: Group sequential clinical trials with triangular continuation regions. Biometrics 39:227, 1983
31. Report of a Concensus Panel from the Immunocompromised Host Society: The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397, 1990
32. Bodey GP, Rodriguez V, Chang HY, Narboni G: Fever and infection in leukemia patients. Cancer 41:1610, 1978
33. Horn R, Wong B, Kiehn T, Armstrong D: Fungaemia in a cancer hospital: Changing frequency, earlier onset and results of therapy. Rev Infect Dis 7:646, 1985
34. Bodey GP: The emergence of fungi as major hospital pathogens. J Hospital Infect 11:411, 1988
35. Bodey GP: What's new in fungal infection in leukemic patients. Leuk Lymphom 11:127, 1993 (suppl 2)
36. Butler WT, Bennet JE, Alling DW, Wertlake PT, Utz JP, Hill GJ: Nephrotoxicity of amphotericin B (early and late effects in 81 patients). Ann Intern Med 61:175, 1964
37. Warda J, Barriere SL: Amphotericin B nephrotoxicity. Drug Intell Clin Pharm 19:25, 1985
38. Haber RH, Oddone EZ, Gurbel PA, Stead WW: Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions. N Engl J Med 315:836, 1986
39. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu RY, Parker VP, Suggs SV, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliot G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Del Castillo J, Biron J, Cole S, Hu MCT, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA: Identification and cloning of a megakaryocte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117, 1994
40. Foster DC, Sprecher CA, Grant FJ, Kramer JM, Kuijper JL, Holly RD, Whitmore TE, Heipel MD, Bell LA, Ching AF, McGrane V, Hart C, O'Hara PJ, Lok S: Human thrombopoietin: Gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 91:13023, 1994
41. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B, Solberg LA, Goeddel DV, Eaton DL: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand [see comments]. Nature 369:533, 1994
42. Metcalf D: Blood. Thrombopoietin - at last [news; comment]. Nature 369:519, 1994
43. de Sauvage FJ, Carver Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 183:651, 1996